DRUG

resveratrol

Dietary supplement; multiple investigational uses

75 hypotheses across 10 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

resveratrol appears in hypotheses across 10 disease domains: ALS, Alzheimer, Depression, Epilepsy, Glioblastoma, Inflammatory bowel disease, Multiple sclerosis, Pancreatic cancer, Rheumatoid arthritis, Type 2 diabetes. Shared mediators that recur across at least two of those domains: SIRT1, miR-21, GSK-3β, EGFR, adiponectin, PTEN.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for resveratrol

ALS 6

Mediator Outcome Score Tier Lit. status Trial
SIRT1 overexpression 0.312 High reproduces known none
AMPK amyotrophic lateral sclerosis 0.208 Mid reproduces known completed
Sod2 blood brain barrier permeability 0.208 Mid reproduces known none
NRF2 neurodegenerative processes 0.208 Mid reproduces known completed
TGF-β1 ALS 0.208 Mid reproduces known completed
Sod2 demyelination 0.208 Mid reproduces known none

Alzheimer 8

Mediator Outcome Score Tier Lit. status Trial
SIRT1 APP transit to endosome 0.312 High novel signal none
SIRT1 tau accumulation 0.312 High partial evidence none
SIRT1 Aβ-induced neurotoxicity 0.312 High partial evidence none
SIRT1 tau acetylation 0.312 High partial evidence none
SIRT1 APP recycling 0.312 High novel signal none
SIRT1 Braak stage 0.312 High novel signal none
GSK-3β tau hyperphosphorylation 0.269 Mid reproduces known none
GSK-3β memory function 0.208 Mid reproduces known completed

Depression 2

Mediator Outcome Score Tier Lit. status Trial
adiponectin MDD 0.269 Mid reproduces known none
Sirt1 depressive symptoms 0.208 Mid reproduces known none

Epilepsy 16

Mediator Outcome Score Tier Lit. status Trial
SIRT1 neuronal cell death 0.312 High reproduces known none
GSK-3β neurodegeneration 0.208 Mid reproduces known completed
PTEN hemimegalencephaly 0.208 Mid novel signal none
PTEN neuroinflammation 0.208 Mid reproduces known active
PTEN cortical malformation 0.208 Mid novel signal none
AMPK epileptiform network activity 0.208 Mid novel signal none
p53 inflammatory marker activation 0.208 Mid novel signal none
AMPK spike-wave seizures 0.208 Mid novel signal none
P-glycoprotein drug-resistant epilepsy 0.208 Mid partial evidence none
p53 seizure 0.208 Mid reproduces known none
PTEN cerebral overgrowth 0.208 Mid novel signal none
NOX2 seizure susceptibility 0.208 Mid novel signal none
P-glycoprotein QT interval prolongation 0.208 Mid partial evidence none
PTEN hyperexcitable circuitry 0.208 Mid novel signal none
P-glycoprotein SUDEP 0.208 Mid novel signal none
PTEN polymicrogyria 0.208 Mid novel signal none

Glioblastoma 5

Mediator Outcome Score Tier Lit. status Trial
EGFR glioblastoma 0.269 Mid reproduces known none
PTEN glioblastoma 0.269 Mid reproduces known none
miR-21 overall survival 0.208 Mid reproduces known none
SOD2 radiation resistance 0.208 Mid partial evidence none
Akt subclonal progression 0.208 Mid novel signal none

Inflammatory bowel disease 4

Mediator Outcome Score Tier Lit. status Trial
miR-21 ulcerative colitis 0.269 Mid reproduces known completed
miR-21 disease activity 0.269 Mid reproduces known completed
Sod2 Reactive arthritis 0.208 Mid novel signal active
PGC1α inflammation 0.208 Mid reproduces known completed

Multiple sclerosis 9

Mediator Outcome Score Tier Lit. status Trial
SIRT1 rheumatoid arthritis 0.312 High reproduces known active
SIRT1 axon demyelination 0.312 High novel signal none
SIRT1 optokinetic response 0.312 High partial evidence none
adiponectin multiple sclerosis 0.269 Mid reproduces known none
adiponectin Multiple Sclerosis Severity Score 0.208 Mid novel signal none
p53 demyelination 0.208 Mid reproduces known none
p53 oligodendrocyte differentiation 0.208 Mid partial evidence none
p53 EAE severity 0.208 Mid novel signal none
p53 white matter damage 0.208 Mid partial evidence none

Pancreatic cancer 15

Mediator Outcome Score Tier Lit. status Trial
SIRT1 proliferation 0.373 High reproduces known preclinical only
SIRT1 patient survival 0.312 High reproduces known none
SIRT1 stemness marker expression 0.312 High partial evidence none
SIRT1 tumor-initiating capacity 0.312 High partial evidence none
EGFR pancreatic ductal adenocarcinoma 0.312 High reproduces known none
SIRT1 proliferation 0.269 Mid reproduces known preclinical only
β-catenin cell invasiveness 0.269 Mid partial evidence none
EGFR pancreatic adenocarcinoma 0.269 Mid partial evidence none
Nrf2 chemoresistance 0.269 Mid reproduces known completed
Sirt1 cell migration 0.269 Mid reproduces known none
SIRT1 proliferation 0.269 Mid reproduces known preclinical only
SIRT1 proliferation 0.269 Mid reproduces known preclinical only
PGC1α cachexia 0.208 Mid reproduces known none
GSK-3β acinar-to-ductal metaplasia 0.208 Mid novel signal none
GSK-3β PanIN progression 0.208 Mid novel signal none

Rheumatoid arthritis 2

Mediator Outcome Score Tier Lit. status Trial
SIRT1 TNF-alpha secretion 0.312 High reproduces known none
miR-21 rheumatoid arthritis 0.269 Mid reproduces known active

Type 2 diabetes 8

Mediator Outcome Score Tier Lit. status Trial
SIRT1 diabetic nephropathy 0.208 Mid reproduces known completed
SIRT1 Type 2 Diabetes Mellitus 0.208 Mid reproduces known active
SIRT1 T2D onset 0.208 Mid novel signal none
SIRT1 inflammation 0.208 Mid reproduces known completed
miR-21 Type 2 Diabetes Mellitus 0.208 Mid reproduces known active
amyloid precursor protein CKD protection 0.208 Mid novel signal none
Nrf2 diabetic cardiomyopathy 0.208 Mid reproduces known none
SIRT1 metabolic dysfunction 0.208 Mid reproduces known active

Clinical trials

200 registered trials for resveratrol

Source: ClinicalTrials.gov

← All drugs